Myelodysplastic Syndrome
Myelodysplastic Syndromes (MDS) are a group of cancers in which blood-forming cells in the bone marrow become abnormal, leading to an insufficient supply of mature, healthy blood cells. Symptoms may include fatigue, shortness of breath, anemia, bleeding disorders, and frequent infections, with some types potentially progressing to acute myeloid leukemia.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Changed Hematology Parameter
- Decreased Serum IgM Levels at 60 Days
- Delayed Onset of Thrombocytopenia
- Developed Anemia
- Improved Blood Index
- Improved Erythroid Response
- Improved Hematological Biomarker
- Improved Hematological Health
- Improved Hematological Parameters
- Improved Hematological Profile
- Increased Cellular Apoptosis
- Increased Dose Tolerance
- Increased Hemocyte Count
- Increased Vitamin B12 Level
- Maintained Blood-Cell Counts
- Prevention of Haematological Parameter Decline
- Reduced Anemia
- Reduced Erythrocyte Count
- Reduced Granulocyte Levels
- Reduced Hematocrit
- Reduced Hematological Index
- Reduced Hemocyte Apoptosis
- Reduced Immune Protection
- Reduced Immunosuppression
- Reduced Monocyte Count
- Reduced Oxidative Stress in Red Blood Cells
- Reduced Packed Cell Transfusion
- Reduced Platelet Counts
- Reduced Thrombocytopenia
- Reduced Transfusion Rate
- Reduced White Blood Cell Count
- Reduced White Blood Cells After Lead Exposure
- Restored Blood Cell Levels